Rokotetutkimuskeskus Finvac Oy

At Rokotetutkimuskeskus Finvac Oy in Tampere, a major share of the work focuses on respiratory tract diseases and virus diseases, especially influenza, respiratory syncytial virus (RSV), COVID-19, and human metapneumovirus. These studies generally aim to test new vaccines and antiviral approaches, while also measuring immune responses and protection in different age groups.

• Influenza prevention and vaccine effectiveness in adults and older adults
• RSV and related respiratory virus protection in infants, children, and seniors
• COVID-19 treatment evaluation in people at higher risk of severe illness

The site’s vaccine-focused expertise supports research on both seasonal and emerging viral threats, with an emphasis on safety, immune response, and real-world protection.

This research site also conducts extensive work in bacterial infections, particularly meningococcal disease, pneumococcal disease, and group B streptococcus (GBS). The trials are designed to evaluate new or improved vaccines, compare immune responses, and strengthen prevention strategies for serious invasive infections.

• Meningococcal immunization in infants, toddlers, children, and adolescents
• Pneumococcal vaccination research for protection against invasive disease
• Maternal vaccination studies aimed at preventing GBS disease in newborns

These programs reflect a strong focus on protecting vulnerable populations from severe bacterial illness through better vaccine-induced immunity.

Several trials at the Tampere Vaccine Clinic address immune system diseases and age-related vulnerability by studying vaccines in older adults. Research includes herpes zoster, high-dose influenza vaccination, and RSV prevention, with the goal of improving protection where immune responses may be weaker.

• Vaccines for shingles and other preventable infections in older adults
• Comparisons of immune response and protection across vaccine options
• Studies of durability and persistence of vaccine-induced immunity

These trials help clarify how well vaccines work over time and whether they can reduce illness burden in aging populations.

The site also contributes to research in immune system processes through studies involving pregnant women, infants, and young children. Trials in this area focus on preventing infections before they become severe, including GBS, RSV, and pneumococcal disease.

• Maternal immunization to protect newborns from early-life infection
• Infant and toddler vaccine studies assessing safety and immune response
• Prevention of serious respiratory and bacterial disease in early childhood

By studying both maternal and pediatric vaccination, the site supports strategies that aim to protect children from the earliest stages of life.

Among the broader portfolio, the site includes work related to nervous system diseases, with research exploring whether vaccination may influence the risk of incident dementia. This type of study looks beyond infection prevention and examines possible longer-term health benefits of immunization.

• Vaccine-related research connected to dementia risk reduction
• Health outcome studies in older adults
• Assessment of broader benefits of preventive vaccination

This adds a distinct public health dimension to the site’s vaccine portfolio, linking infectious disease prevention with aging and brain health.

Across its trial portfolio, Rokotetutkimuskeskus Finvac Oy supports a wide range of vaccine development programs that compare immune responses, evaluate safety, and measure how well candidate vaccines prevent disease. The research spans multiple pathogens, from yellow fever to cytomegalovirus (CMV), showing a broad commitment to preventive medicine.

• Evaluation of candidate vaccines against viral and bacterial infections
• Measurement of antibody responses and protection after vaccination
• Studies designed to improve prevention in both healthy and at-risk populations

Overall, the site serves as an active clinical research center for testing new immunization strategies and improving protection against important infectious diseases.